Hong Zhu

Dr. Hong Zhu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
LHLing Hou
Ling Hou
KHKe Huang
Ke Huang
CGChunxiu Gong
Chunxiu Gong
FLFeihong Luo
Feihong Luo
WHwei haiyan
wei haiyan
Xiaoping LuoXiaoping Luo
Xiaoping Luo
Context The evidence of long-term polyethylene glycol recombinant human GH (PEG-rhGH) in pediatric GH deficiency (GHD) is limited. Objective This study aimed to examine the effectiveness and safety of long-term PEG-rhGH in children with GHD in the real world, as well as to examine the effects of dose on patient outcomes. Design A prospective, observational, posttrial study (NCT03290235). Setting, participants and intervention Children with GHD were enrolled from 81 centers in China in 4 individual clinical trials and received weekly 0.2 mg/kg/wk (high-dose) or 0.1 to <0.2 mg/kg/wk (low-dose) PEG-rhGH for 30 months. Main outcomes measures Height SD score (Ht SDS) at 12, 24, and 36 months. Results A total of 1170 children were enrolled in this posttrial study, with 642 patients in the high-dose subgroup and 528 in the low-dose subgroup. The Ht SDS improved significantly after treatment in the total population (P < 0.0001), with a mean change of 0.53 ± 0.30, 0.89 ± 0.48, 1.35 ± 0.63, 1.63 ± 0.75 at 6 months, 12 months, 24 months, and 36 months, respectively. In addition, the changes in Ht SDS from baseline were significantly improved in the high-dose subgroup compared with the low-dose subgroup at 6, 12, 24, and 36 months after treatment (all P < 0.05). A total of 12 (1.03%) patients developed serious adverse events. There was no serious adverse event related to the treatment, and no AEs leading to treatment discontinuation or death occurred. Conclusions PEG-rhGH showed long-term effectiveness and safety in treating children with GHD. Both dose subgroups showed promising outcomes, whereas PEG-rhGH 0.2 mg/kg/wk might show additional benefit.

11 July 2023 in Journal of Trauma & Dissociation
Verified
Journal Article
Closed access
SWSici Wang
Sici Wang
SZSisi Zheng
Sisi Zheng
FZFrancis Xiaitan Zhang
Francis Xiaitan Zhang
RMRui Ma
Rui Ma
SFSitong Feng
Sitong Feng
HJHongxiao Jia
Hongxiao Jia
Depersonalization-derealization disorder (DPD) is characterized by persistent or recurrent experiences of detachment from oneself and surroundings, as well as a sense of unreality. Considering the inadequacy of current research on treatment, we performed a systematic review of the available pharmacotherapies, neuromodulations, and psychotherapies for DPD. The systematic review protocol was based on PRISMA 2020 guidelines and pre-registered. The PubMed, Web of Science, PsycINFO, Embase, the Cochrane Library, Scopus, and ScienceDirect databases were searched from inception to June 2021. All treatments for DPD and all study types, including controlled and observational studies as well as case reports, were assessed. Of the identified 17,540 studies, 41 studies (four randomized controlled trials, one non-randomized controlled trial, 10 case series, and 26 case reports) involving 300 participants met the eligibility criteria. We identified 30 methods that have been applied independently or in combination to treat DPD since 1955. The quality of these studies was considered. The relationship between individual differences, such as symptoms, comorbidities, history, and duration since onset, and treatment effects was explored. The results suggest that a series of treatments, such as pharmacotherapies, neuromodulation, and psychotherapies, could be considered in combination. However, the quality and quantity of studies were generally low considering the high prevalence of DPD. The review concludes with suggestions for future research and an urgent call for more high-quality research.

21 August 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
SZSisi Zheng
Sisi Zheng
NSNan Song
Nan Song
SWSici Wang
Sici Wang
YNYanzhe Ning
Yanzhe Ning
HZHong Zhu
Hong Zhu
HJHongxiao Jia
Hongxiao Jia
Introduction: Non-invasive brain stimulation seems to be beneficial for DPD patients. However, the sites used in previous studies were empirical. Exploring new stimulation locations via functional magnetic resonance imaging may improve the efficacy. Objectives: The objective was to find potential locations for non-invasive brain stimulation on the depersonalization-derealization disorder. Methods: We explored the potential brain surface regions from three pipelines: pipeline 1: activation likelihood estimation meta-analysis (five studies with 36 foci included); pipeline 2: functional connectivity analysis based on DPD-network (76 subjects included); and pipeline 3: functional connectivity analysis based on DPD regions of interest from the meta-analysis. Potential targets were the 10–20 system coordinates for brain surface regions. Results: We identified several potential brain surface regions, including the bilateral medial prefrontal cortex, dorsal lateral prefrontal cortex, superior parietal gyrus, superior temporal gyrus, and right ventrolateral prefrontal cortex as potential sites. Conclusion: Our findings of the potential stimulation targets might help clinicians optimize the application of non-invasive brain stimulation therapy in individuals with DPD.

22 November 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
SLShanshan Liu
Shanshan Liu
YJYuan Jia
Yuan Jia
SZSisi Zheng
Sisi Zheng
SFSitong Feng
Sitong Feng
HZHong Zhu
Hong Zhu
HJHongxiao Jia
Hongxiao Jia
The self-perception or self-experience of patients with depersonalization/derealization disorder (DPD) is altered, leading to a profound disruption in self-awareness. The main aim of the study is to explore the characteristics of subliminal self-face processing in DPD patients. To our knowledge, this is the first experimental study that has measured and evaluated subliminal self-processing in DPD. To better understand this, we examined the ability of patients with DPD and healthy controls (HC) to identify pictures of faces using an experimental paradigm of breaking continuous flash suppression. There were 23 DPD outpatients from Beijing Anding Hospital, Capital Medical University and 23 matched HC who participated in this experiment. The time needed for a face to break into awareness was taken as the measure of participants’ subliminal processing of that face. The results indicated that there were significant differences between the DPD patients and HC in subliminal reaction times to different faces. Under experimental conditions, the average reaction response of self-face recognition in the HC group was significantly faster than for a famous face. However, this difference was not observed in DPD patients, which means that DPD patients did not show the processing advantage of their own faces as did the HC. The results suggest a deficit in subliminal self-face processing in DPD.

14 March 2020 in Trials
Verified
Journal Article
Open access
PDF file
PCPei Chen
Pei Chen
HZHong Zhu
Hong Zhu
YNYanzhe Ning
Yanzhe Ning
DYDongqing Yin
Dongqing Yin
HJHongxiao Jia
Hongxiao Jia
Background: Generalized anxiety disorder (GAD) is a persistent and common mental disorder that entails significant impairments in role functioning and quality of life. Currently available effective interventions include psychological therapies, self-help approaches, and pharmacological treatments, which do not quite meet clinical needs, and the ideal anxiolytic is still being sought. Shu-gan-qing-re (SGQR) formula, a Chinese patent medicine, has been well received by patients with GAD in Chinese clinical practice for years. The present prospective, double-blind, double-dummy, randomized controlled trial is designed to investigate the efficacy and safety of SGQR formula for GAD. Methods/design: A total of 200 eligible participants will be recruited from four hospitals in different parts of China. They will be randomly assigned to either the study group or the control group in a ratio of 1:1. Participants allocated to the study group will receive SGQR formula and buspirone placebo, while buspirone and SGQR placebo will be applied in the control group. Six scheduled visits will be conducted over the course of 8 weeks. Outcome measurements include Hamilton Anxiety Rating Scale (HAM-A), Hamilton Depression Rating Scale-17 (HAMD-17), Clinical Global Impression-Improvement Scale (CGI-I), Traditional Chinese Medicine Syndrome Scale for GAD, and pro-inflammatory cytokine tests: interleukin-1 beta (IL-1β), IL-6, and tumor necrosis factor-alpha. Adverse reactions will be evaluated by using the Treatment Emergent Symptom Scale (TESS). Safety outcomes and adverse events will also be recorded. Discussion: The study will provide scientific and objective assessments for the efficacy and safety of SGQR formula for patients with GAD, hopefully offering clinicians an alternative approach to GAD. Trial registration: Chinese Clinical Trial Registry, ID: ChiCTR-IPR-17013058. Registered on October 20, 2017.

17 January 2026 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
YHYue He
Yue He
FZFrancis Xiatian Zhang
Francis Xiatian Zhang
XWXiaxia Wu
Xiaxia Wu
MFMeng Fang
Meng Fang
SZSisi Zheng
Sisi Zheng
HZHong Zhu
Hong Zhu
Background: Artificial intelligence (AI) is receiving growing attention in psychiatric practice, yet psychiatrists vary considerably in how they perceive its benefits, risks, and clinical usefulness. Successful implementation depends not only on technological performance but also on clinicians’ readiness, including their access to AI, confidence in using it, trust in its reliability, and expectations for its design. Evidence on these dimensions remains limited in China. Objective: This study examined Chinese psychiatrists’ readiness for AI across four dimensions—access, self-efficacy, trust, and design expectations—and explored variation across demographic and professional subgroups. Method: A cross-sectional online survey was distributed through the WeChat platform from March 20 to 22, 2025. Eligible participants were licensed psychiatrists engaged in clinical practice. A total of 134 valid responses were obtained from clinicians across diverse provinces, hospital tiers, and professional roles. Descriptive analyses and group comparisons were conducted. Results: Psychiatrists reported broad exposure to AI, though knowledge was largely acquired through informal rather than structured sources. Overall self-efficacy was moderate, with higher confidence observed among younger clinicians, male clinicians, and those who had received AI-related training. Trust in AI was generally positive, and department heads expressed especially strong confidence in its future role. Across subgroups, psychiatrists consistently prioritized AI applications that reduce administrative and documentation burden, while expressing lower expectations for AI use in communication, assessment, or psychotherapy. Conclusion: Chinese psychiatrists demonstrated cautious optimism and moderate readiness for AI. Limited access to formal training and subgroup differences in confidence highlight the need for targeted capacity-building. The strong preference for documentation-support tools underscores the importance of designing AI systems that integrate smoothly into clinical workflows while preserving the human-centered nature of psychiatric care.